Business Context and Reporting Period
This Form 8-K Current Report was filed by Karyopharm Therapeutics Inc. on December 6, 2021, covering events occurring on December 2 and December 3, 2021. The filing addresses changes to the composition of the Company's Board of Directors.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on corporate governance changes and director compensation arrangements.
Material Changes
- Resignation: Mikael Dolsten, MD, PhD, resigned from the Board of Directors effective December 2, 2021, due to competing professional demands. The resignation was not the result of any disagreement with the Company.
- Election: Peter K. Honig, M.D., MPH, was elected as an independent director on December 3, 2021, to fill the vacancy. He was designated as a Class III director with a term expiring at the 2022 annual meeting.
- Committee Appointment: Dr. Honig was appointed to the Commercialization and Portfolio Committee.
Compensation and Governance Details
In connection with his election, Dr. Honig received the following compensation under the Company's Non-employee Director Compensation Policy:
- Cash Retainer: $50,000 annual retainer for Board service and $10,000 for Committee service, prorated based on the appointment date.
- Equity Grant: An option to purchase 47,800 shares of common stock under the 2013 Stock Incentive Plan.
- Option Terms: Exercise price of $6.72 (closing price on grant date). Vesting schedule includes one-third on the first anniversary, followed by monthly vesting of 1/36th of the total shares until the third anniversary.
- Indemnification: The Company entered into a standard indemnification agreement with Dr. Honig.
Investor Verification Checklist
- Verify the impact of Dr. Dolsten's departure on the Board's expertise and oversight capabilities.
- Review Dr. Honig's background and qualifications to assess his fit for the Commercialization and Portfolio Committee.
- Confirm the dilution impact of the 47,800 share option grant on existing shareholders.
- Check for any undisclosed relationships or conflicts of interest involving the new director.